TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23788694

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 168
Study: 21291444

Group type: EXPERIMENTAL
Intervention: KiVa antibullying program
Number of subjects: 8237

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8237
Study: 19849996

Group type: EXPERIMENTAL
Intervention: Intradermal trivalent inactivated seasonal influenza vaccine (15 microg of haemagglutinin per strain per 0.1 ml dose)
Number of subjects: 3707

Group type: EXPERIMENTAL
Intervention: Intradermal trivalent inactivated seasonal influenza vaccine
Number of subjects: 3707

Group type: COMPARATOR
Intervention: Conventional intramuscular vaccine
Number of subjects: 3707

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 3707
Study: 16452696

Group type: EXPERIMENTAL
Intervention: Community-based representative payeeship coordinated with psychiatric care
Number of subjects: 184

Group type: COMPARATOR
Intervention: Customary clinical care
Number of subjects: 184
Study: 15315995

Group type: EXPERIMENTAL
Intervention: Fluoxetine with CBT (10 to 40 mg/d)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine alone (10 to 40 mg/d)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: CBT alone
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo (equivalent to 10 to 40 mg/d)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine with CBT
Number of subjects: 439
Study: 11699608

Group type: EXPERIMENTAL
Intervention: E 5 mg (intranasal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: E 10 mg (intranasal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: E 50 mg (oral)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9814459

Group type: EXPERIMENTAL
Intervention: Standardized regimen of calcium supplements and phosphorus binders, no vitamin D derivatives
Number of subjects: 52
Study: 7640329

Group type: EXPERIMENTAL
Intervention: m-CPP (0.1 mg/kg) in untreated conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Light treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: m-CPP in untreated winter subjects
Number of subjects: 36

Group type: COMPARATOR
Intervention: m-CPP in summer subjects
Number of subjects: 36
Study: 2752859

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (4000 cGy for 4 weeks) plus surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgical treatment without preoperative measures
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (4000 cGy for 4 weeks)
Number of subjects: 68
Study: 593989

Group type: EXPERIMENTAL
Intervention: Topical application of indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultraviolet B (u.v.‐B) irradiation
Number of subjects: 0
Study: 31831599

Group type: EXPERIMENTAL
Intervention: SAIL technique
Number of subjects: 110

Group type: COMPARATOR
Intervention: ICL technique
Number of subjects: 110
Study: 31507219

Group type: EXPERIMENTAL
Intervention: CT-P6 (trastuzumab-pkrb, Herzuma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-P6
Number of subjects: 0
Study: 29196479

Group type: EXPERIMENTAL
Intervention: Digital cognitive-behavioural therapy for insomnia (CBT-I) for 6 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Online puzzle activity for 6 weeks
Number of subjects: 240
Study: 26485217

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU orally once weekly for 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (oral placebo once weekly for 8 weeks)
Number of subjects: 68
Study: 22576822

Group type: EXPERIMENTAL
Intervention: Video clips advance organizers (AO)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Prosection advance organizers (AO)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 141
Study: 21741720

Group type: EXPERIMENTAL
Intervention: Concurrent re‐irradiation, fluorouracil and hydroxyurea (R‐RT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Methotrexate (Ch‐T)
Number of subjects: 57
Study: 19591339

Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste with triclosan
Number of subjects: 1357

Group type: COMPARATOR
Intervention: Colgate sodium fluoride toothpaste without triclosan
Number of subjects: 1357
Study: 16998133

Group type: EXPERIMENTAL
Intervention: School dental screening (3 different models)
Number of subjects: 16864

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16864
Study: 12881261

Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide
Number of subjects: 107

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 107
Study: 10838988

Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialists (CNSs) present on units
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Clinical Nurse Specialists (CNSs) on units
Number of subjects: 0
Study: 7475425

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2012354

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus loperamide (4 mg first dose, 2 mg for every loose stool, max 16 mg/d)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ciprofloxacin alone (placebo)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus loperamide
Number of subjects: 104
Study: 7032948

Group type: EXPERIMENTAL
Intervention: Cholestyramine/alginates/bicarbonate (CAB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2994512

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 0
Study: 29499208

Group type: EXPERIMENTAL
Intervention: Water vapor thermal therapy (Rezūm® System)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Any medical therapy (doxazosin and/or finasteride)
Number of subjects: 1140
Study: 27085561

Group type: EXPERIMENTAL
Intervention: Music (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-music (n = 20)
Number of subjects: 40
Study: 24225048

Group type: EXPERIMENTAL
Intervention: Post-activation potentiation (PAP) with 3 × 3-second maximal isometric squats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-activation potentiation (PAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control protocol (without PAP)
Number of subjects: 0
Study: 22967972

Group type: EXPERIMENTAL
Intervention: Narcotrend monitor
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (routine method)
Number of subjects: 80
Study: 20088735

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19087695

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules, orally 4 days before operation once daily and then via nasal feeding tube after operation once a day for 5 days
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 87
Study: 16153398

Group type: EXPERIMENTAL
Intervention: 5 mg mosapride (3 times daily for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg administered after morphine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mosapride in rats (100 mg/kg orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone in rats
Number of subjects: 12
Study: 12057728

Group type: EXPERIMENTAL
Intervention: Removal of necrotic blastomeres from frozen‐thawed human embryos
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (necrotic blastomeres not removed)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Removal of necrotic blastomeres from all partially damaged embryos
Number of subjects: 235
Study: 10480153

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) given five minutes before meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) given during meals
Number of subjects: 12
Study: 8607671

Group type: EXPERIMENTAL
Intervention: Same-day admission
Number of subjects: 276
Study: 1932450

Group type: EXPERIMENTAL
Intervention: Selective decontamination with 4 x 100 g polymyxin E, 4 x 80 mg tobramycin and 4 x 500 mg amphotericin B administered through the gastric tube and with an antimicrobial sticky paste in the oropharynx (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50 mg of polymyxin B and 80 mg of gentamicin dissolved in 10 ml of 0.9% saline at 6 h intervals into nose, oropharynx and stomach as well as 300 mg of amphotericin B in the oropharynx only (group II)
Number of subjects: 40
Study: 6757842

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31586639

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (D3 B.O.N®), 200,000 IU at 1 month and 200,000 IU at 6 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (non-supplemented children)
Number of subjects: 150
Study: 31085285

Group type: EXPERIMENTAL
Intervention: Nomogram developed from MA.20 trial data
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Nomogram validated externally
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Extent of axillary surgery
Number of subjects: 1832

Group type: EXPERIMENTAL
Intervention: Extent of nodal irradiation
Number of subjects: 1832
Study: 29194851

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 488
Study: 26434665

Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Lantus® insulin glargine (IGlar)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Prior IGlar subgroup of patients with T2DM
Number of subjects: 1291
Study: 25103657

Group type: EXPERIMENTAL
Intervention: 30°C OVDs
Number of subjects: 4

Group type: COMPARATOR
Intervention: Room temperature OVDs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 26°C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 32°C
Number of subjects: 4
Study: 21960113

Group type: EXPERIMENTAL
Intervention: Truncal/chest/arm advanced pneumatic compression therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Arm only pneumatic compression
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 19960145

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention (physician contact with supervisor and occupational physiotherapist ergonomic assessment)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (no ergonomic intervention)
Number of subjects: 177
Study: 18632412

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC group, n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cyclosporine (CsA group, n = 20)
Number of subjects: 41
Study: 16199745

Group type: EXPERIMENTAL
Intervention: Audit and feedback together with academic detailing and practice guidelines
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Audit and feedback together with seminars and practice guidelines
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Audit and feedback alone
Number of subjects: 20
Study: 12243636

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1326
Study: 10473005

Group type: EXPERIMENTAL
Intervention: Mapping-enhanced counseling
Number of subjects: 381

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 381
Study: 8938897

Group type: EXPERIMENTAL
Intervention: Ethanolamine oleate
Number of subjects: 78

Group type: COMPARATOR
Intervention: Absolute ethanol
Number of subjects: 78
Study: 2010437

Group type: EXPERIMENTAL
Intervention: Aspirin (85‐325 mg daily up to or within 48 hours of surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No aspirin (discontinued at least 4 days before surgery)
Number of subjects: 100
Study: 7104563

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NS)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Paracetamol/dextropropoxyphene (control)
Number of subjects: 184
Study: 29556866

Group type: EXPERIMENTAL
Intervention: AZD5672 (experimental compound)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LQMM method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bootstrap CI calculation methods
Number of subjects: 0
Study: 26655857

Group type: EXPERIMENTAL
Intervention: Nursing process-based simulation training program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional methods of training for maternal and child emergency nursing care
Number of subjects: 49
Study: 24332324

Group type: EXPERIMENTAL
Intervention: Preemptive lornoxicam 8 mg intravenously 25 minutes before surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Postoperative lornoxicam
Number of subjects: 43
Study: 22804901

Group type: EXPERIMENTAL
Intervention: Lactate analysis in SGA fetuses
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Lactate analysis in AGA fetuses
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Lactate analysis in LGA fetuses
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Lactate analysis in SGA fetuses with lactacidaemia
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Lactate analysis in AGA fetuses with lactacidaemia
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Lactate analysis in LGA fetuses with lactacidaemia
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Cord artery pH < 7.00
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Metabolic acidaemia
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Apgar score <7 at 5 minutes
Number of subjects: 1496
Study: 20175406

Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 17115388

Group type: EXPERIMENTAL
Intervention: Immediate-release levodopa (IR LD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controlled-release levodopa (not specified if used in this context)
Number of subjects: 14
Study: 15625351

Group type: EXPERIMENTAL
Intervention: Divalproex sodium 1000 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12212876

Group type: EXPERIMENTAL
Intervention: Warmed local anesthetic solution (37 degrees C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Room-temperature local anesthetic solution (21 degrees C)
Number of subjects: 44
Study: 9469393

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cefprozil (after crossover)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Penicillin (after crossover)
Number of subjects: 49
Study: 8597874

Group type: EXPERIMENTAL
Intervention: rBPI23 (1 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (human serum albumin, 0.2 mg/kg)
Number of subjects: 8
Study: 2698046

Group type: EXPERIMENTAL
Intervention: methylprednisolone (mPSL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: antilymphocyte globulin (ALG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: antithymocytoglobulin (ATG)
Number of subjects: 100
Study: 1211323

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30253725

Group type: EXPERIMENTAL
Intervention: Intensive pharmacist intervention at the beginning of oral antineoplastic therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nurse-led control group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (pharmacist and nurse-led)
Number of subjects: 200
Study: 27903559

Group type: EXPERIMENTAL
Intervention: Diabetes-specific message with enhanced active choice (EAC)
Number of subjects: 3665

Group type: EXPERIMENTAL
Intervention: Diabetes-specific message alone
Number of subjects: 3665

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3665
Study: 24856027

Group type: EXPERIMENTAL
Intervention: Left ventricular end‐diastolic pressure‐guided volume expansion (n=196)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Standard fluid administration protocol (Control group, n=200)
Number of subjects: 396
Study: 22382482

Group type: EXPERIMENTAL
Intervention: Decentralized clinical pharmacy services (CPOMS)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Centralized registered nurse management (comparison group)
Number of subjects: 1129
Study: 20715601

Group type: EXPERIMENTAL
Intervention: Sprinkles micronutrient powders
Number of subjects: 550
Study: 18772724

Group type: EXPERIMENTAL
Intervention: Balafilcon A (PureVision) lens
Number of subjects: 22

Group type: COMPARATOR
Intervention: Galyfilcon A (Acuvue Advance) lens
Number of subjects: 22
Study: 16631046

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Perioperative topical levofloxacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14960217

Group type: EXPERIMENTAL
Intervention: Multifaceted support (conferences, dissemination of manuals, support from trained non-physicians during outreach visits)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Multifaceted support
Number of subjects: 617

Group type: COMPARATOR
Intervention: No special attention (control group)
Number of subjects: 617
Study: 11105102

Group type: EXPERIMENTAL
Intervention: Arousing story
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutral story
Number of subjects: 46
Study: 8629932

Group type: EXPERIMENTAL
Intervention: Tehlin knee
Number of subjects: 28

Group type: COMPARATOR
Intervention: 3R20 knee
Number of subjects: 28
Study: 7910321

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (mitomycin, doxorubicin, and fluorouracil)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 436
Study: 3213065

Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate) 1000 mg (2 x 1 capsule) daily for 8 weeks (2 weeks preoperatively and 6 weeks postoperatively)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 120
Study: 30945151

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg once daily for 6 months postoperatively
Number of subjects: 189
Study: 28532702

Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg twice daily for 72 hours, starting 48 hours before the procedure, in addition to isotonic saline hydration.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isotonic saline hydration only (control group).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg twice daily for 72 hours, starting 48 hours before the procedure, in conjunction with isotonic saline hydration.
Number of subjects: 100
Study: 27883324

Group type: EXPERIMENTAL
Intervention: Hormone therapy (50 μg transdermal oestradiol, 5 mg MPA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23246272

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with 5-fluorouracil (57% of patients)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Trabeculectomy without 5-fluorouracil
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 285
Study: 20671103

Group type: COMPARATOR
Intervention: Conventional glucose-containing dialysis solution (group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low level GDP fluid (group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Residual renal function (RRF) in group A
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Residual renal function (RRF) in group B
Number of subjects: 23
Study: 19777463

Group type: COMPARATOR
Intervention: Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 17075233

Group type: EXPERIMENTAL
Intervention: Italian version of the Body Cathexis Scale (BCS)
Number of subjects: 490
Study: 15603207

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 11282902

Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban plus aspirin (LDS+A)
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban (HDS)
Number of subjects: 6671

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 6671
Study: 8777774

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (1.5 mg/kg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 2042259

Group type: EXPERIMENTAL
Intervention: Hydroxylapatite
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Kiel bone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (empty iliac crest)
Number of subjects: 104
Study: 6386897

Group type: EXPERIMENTAL
Intervention: Folate mouthwash (5 ml twice daily for 4 weeks, containing 5 mg folate per 5 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 60
Study: 30545576

Group type: EXPERIMENTAL
Intervention: 5-day decitabine schedule
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 10-day decitabine schedule
Number of subjects: 71
Study: 28419379

Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic to a peripheral pain generator (MTrP or other discrete tender point)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic
Number of subjects: 31
Study: 25667151

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention targeting identified characteristics of frailty and problems identified during geriatric assessment for 12 months.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 230